Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων
With a limited follow-up, the German experience (203 pts)
with SOC
CAR-T cells in LBCL is in keeping with the approval trials in
terms of
safety, whereas our efficacy data appear to be inferior to
published
results.
ABSTRACT EBMT
AA2-2 STANDARD-OF-CARE CAR-T CELL THERAPY FOR LARGE B-CELL
LYMPHOMA:
REAL WORLD...
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Presenter: Dr Liga
Participants: Prof.Spyridonidis, Dr Tsokanas, Dr Lekka
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Excellent review on HMA, their clinical use and
mechnisms on
resistance.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Comprehensive excellent review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370557/
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Journal of Clinical Oncology. 2021 Apr 27;
National Marrow Donor
Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched
Unrelated Donor Bone Marrow Transplantation Using Post-Transplant
Cyclophosphamide.
Bronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns,
Brent R Logan, Farhad Khimani, Brian C Shaffer, Nirav N Shah,
Alisha Mussetter,...
Cancer. 2021 Mar 18;
Acute myeloid leukemia:
Treatment and research outlook for 2021 and the MD Anderson
approach.
Hagop M Kantarjian, Tapan M Kadia, Courtney D DiNardo, Mary
Alma Welch, Farhad Ravandi
PMID: 33734442
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Excellent case based report on npm1 Mut Aml
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Comprehensive review for AML treatment. New directions
applied in MD Anderson CC
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
New guidelines for treatment of MM (EHA/ESMO)
Presenter S. Kastritis
Participation Spyridonidis, Liga, Tsokanas
Diagnostic obligatory are still Free light chain serum, 24-Urin,
cytogenetics (Del17p, t(4,14), WBLD-CT and if negative Whole
body MRI.
Asymptomatic MM (use 20/2/20 score), if high (2 of 3) risk score
these pats...
https://www.ebmt.org/sites/default/files/2021-02/EBMT%20COVID-19%20guidelines%20v.%2015.02%202021-02-18.pdf
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Ebmt proposes to vaccinate after day 100
https://www.ecdc.europa.eu/en/publications-data/coronavirus-disease-2019-covid-19-and-supply-substances-human-origin
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka
An important paper published in Blood showed that prophylaxis
is not
always wihtout harm. Pts under letermovir prophylaxis may be
at risk for
late CMV infection after HCT because of delay CMV-specific
cellular
reconstitution (which is due to the letermovir induced
decreased CMV
antigen exposure).
JOURNAL ARTICLE
Cytomegalovirus-specific T-cell Reconstitution...
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Lekka